Researchers at Biogen Idec (NASDAQ: BIIB), a global biotechnology leader with products and capabilities in oncology, neurology and immunology, reported in the August 15, 2006 issue of the Journal of Immunology that activation of a recently discovered inflammation pathway may play an important role in the disease process that causes rheumatoid arthritis (RA). The studies advance the understanding of RA and demonstrate that inhibiting the TWEAK molecule may provide a new approach to developing RA treatments.
